BioNTech SE — Company profile
Healthcare · Biotechnology · Germany
Last price 87.715 USD (Oct 30, 2026, 2:19 PM EDT) · Market cap 22.03B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Details
| Name | BioNTech SE |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 7807 |
| Founded | 2008 |
| Ipo Date | 2019-10-10 |
| Ceo | Ugur Sahin |
| Country | Germany |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| Ipo Price | 15.00 |
| Isin | US09075V1026 |
| Cusip | 09075V102 |
| Cik | 1776985 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Dr. Ugur Sahin M.D. | Co-Founder, Chief Executive Officer and Chair of the Management Board |
| Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer and Member of Management Board |
| Ramon Zapata-Gomez | Chief Financial Officer and Member of Management Board |
| Dr. Sierk Pötting Ph.D. | MD, Chief Operating Officer and Member of Management Board |
| Dr. James Timothy Patrick Ryan Ph.D. | Chief Legal and Business Officer and Member of the Management Board |
| Annemarie Hanekamp | Chief Commercial Officer and Member of Management Board |
| Kylie Jimenez | Chief People Officer and Member of Management Board |
| Lisa Birringer | Senior Vice President of Global Financial Reporting and Accounting |
| Douglas Maffei Ph.D. | Vice President of Strategy and Investor Relations |
| Jasmina Alatovic | Vice President Corporate Communications |
Contact
| Address | An der Goldgrube 12, Mainz, 55131, Germany |
| Phone | 49 6131 9084 |
| Website | https://www.biontech.de |